CytomX Therapeutics
This role provides strategic and operational leadership for safety and pharmacovigilance activities across CytomX clinical development programs, reporting directly to the Chief Medical Officer. The position serves as a senior safety subject-matter expert, leading cross-functional benefit-risk evaluations, safety surveillance, and regulatory safety deliverables. The role is responsible for building out safety and pharmacovigilance capabilities to support global late-stage development of varsetatug masetecan and potential regulatory approval.
Headquarters
South San Francisco, California, United States
Company Size
51-200 employees
CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on researching and developing innovative cancer therapies. The company pioneered Probody® therapeutics, a versatile platform designed to unlock the full potential of more potent, less toxic cancer medications, including antibody-drug conjugates (ADCs). CytomX's pipeline includes multiple Probody programs in the clinic, with a lead candidate targeting colon cancer treatment.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for CytomX Therapeutics.
Vice President, Pharmacovigilance & Risk Management
Celldex Therapeutics
Pharmacovigilance Strategy & Leadership
Rezolute
Head of Global Pharmacovigilance
Disc Medicine
Vice President, Pharmacovigilance and Drug Safety (Head of Pharmacovigilance and Drug Safety)
ORIC Pharmaceuticals Inc
Medical Director Pharmacovigilance
Jobgether
Director, Drug Safety & Pharmacovigilance - Safety Scientist
Travere Therapeutics